Literature DB >> 32916125

Epigenomic Reprogramming as a Driver of Malignant Glioma.

Richard E Phillips1, Alexey A Soshnev2, C David Allis3.   

Abstract

Malignant gliomas are central nervous system tumors and remain among the most treatment-resistant cancers. Exome sequencing has revealed significant heterogeneity and important insights into the molecular pathogenesis of gliomas. Mutations in chromatin modifiers-proteins that shape the epigenomic landscape through remodeling and regulation of post-translational modifications on chromatin-are very frequent and often define specific glioma subtypes. This suggests that epigenomic reprogramming may be a fundamental driver of glioma. Here, we describe the key chromatin regulatory pathways disrupted in gliomas, delineating their physiological function and our current understanding of how their dysregulation may contribute to gliomagenesis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chromatin; epigenomics; glioma; transcription

Mesh:

Substances:

Year:  2020        PMID: 32916125     DOI: 10.1016/j.ccell.2020.08.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  19 in total

1.  Sox9 directs divergent epigenomic states in brain tumor subtypes.

Authors:  Debosmita Sardar; Hsiao-Chi Chen; Amanda Reyes; Srinidhi Varadharajan; Antrix Jain; Carrie Mohila; Rachel Curry; Brittney Lozzi; Kavitha Rajendran; Alexis Cervantes; Kwanha Yu; Ali Jalali; Ganesh Rao; Stephen C Mack; Benjamin Deneen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-15       Impact factor: 12.779

Review 2.  The language of chromatin modification in human cancers.

Authors:  Shuai Zhao; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2021-05-17       Impact factor: 60.716

3.  Oncogenic magnesium transporter 1 upregulates programmed death-1-ligand 1 expression and contributes to growth and radioresistance of glioma cells through the ERK/MAPK signaling pathway.

Authors:  Yuanyuan Wu; Hongbing Wang; Dongdong Wei
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.

Authors:  Swati Dhar; Samantha Gadd; Priyam Patel; Jake Vaynshteyn; G Praveen Raju; Rintaro Hashizume; Daniel J Brat; Oren J Becher
Journal:  Acta Neuropathol Commun       Date:  2022-04-08       Impact factor: 7.801

5.  Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression.

Authors:  Feifei Cheng; Jiang Liu; Yundong Zhang; Qiuxiang You; Bo Chen; Jing Cheng; Chunyan Deng
Journal:  Cancer Manag Res       Date:  2021-01-14       Impact factor: 3.989

6.  EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3.

Authors:  Ziwen Pan; Rongrong Zhao; Boyan Li; Yanhua Qi; Wei Qiu; Qindong Guo; Shouji Zhang; Shulin Zhao; Hao Xu; Ming Li; Zijie Gao; Yang Fan; Jianye Xu; Huizhi Wang; Shaobo Wang; Jiawei Qiu; Qingtong Wang; Xing Guo; Lin Deng; Ping Zhang; Hao Xue; Gang Li
Journal:  Mol Cancer       Date:  2022-01-14       Impact factor: 27.401

7.  Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma.

Authors:  L Eric Huang
Journal:  Biomedicines       Date:  2022-01-24

8.  A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.

Authors:  Haitao Luo; Chuming Tao; Xiaoyan Long; Kai Huang; Xingen Zhu
Journal:  Aging (Albany NY)       Date:  2021-06-10       Impact factor: 5.682

9.  METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner.

Authors:  Jia Shi; Gang Chen; Xuchen Dong; Haoran Li; Suwen Li; Shan Cheng; Yongdong Li; Liping Wang; Jiaqi Yuan; Zhiyuan Qian; Jun Dong
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

10.  BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.

Authors:  Olga Gusyatiner; Pierre Bady; Minh D T Pham; Yvonne Lei; Jungyeon Park; Roy T Daniel; Mauro Delorenzi; Monika E Hegi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.